Get a free sample of Non-alcoholic Steatohepatitis Treatment Market
Thank you!
Your inquiry has been received. Our team will reach out to you with the required details via email. To ensure that you don't miss their response, kindly remember to check your spam folder as well!
Form submitted successfully!
Error submitting form. Please try again.
Get a free sample of Non-alcoholic Steatohepatitis Treatment Market
Thank you!
Your inquiry has been received. Our team will reach out to you with the required details via email. To ensure that you don't miss their response, kindly remember to check your spam folder as well!
Form submitted successfully!
Error submitting form. Please try again.
Non-alcoholic Steatohepatitis Treatment Market Size
Non-alcoholic Steatohepatitis Treatment Market size accounted for USD 5.5 billion in 2023 and is expected to grow at 29.9% of CAGR from 2024 to 2032. The market is driven by several factors, including the increasing prevalence of metabolic disorders, primarily due to the rising incidence of obesity and type 2 diabetes, as well as the growing awareness of NASH as a serious health condition.
For instance, according to a World Health Organization (WHO) report, in 2022, 43% of adults aged 18 years and above were overweight, and 16% were living with obesity worldwide, leading to a higher risk of developing NASH. This underscores the substantial burden of metabolic diseases on global health. Consequently, innovative treatment approaches, such as the development of new drug therapies and lifestyle intervention strategies focusing on weight loss and obesity management, have created new opportunities for enhancing patient care, thereby propelling market growth.
The non-alcoholic steatohepatitis (NASH) treatment market encompasses the development, production, and distribution of therapeutic solutions targeting NASH, a severe form of non-alcoholic fatty liver disease characterized by liver inflammation and damage caused by a buildup of fat in the liver.
Who are the major non-alcoholic steatohepatitis treatment industry players?
AstraZeneca, Bristol-Myers Squibb Company, Conatus Pharmaceuticals, Galmed Pharmaceuticals, Genfit, Gilead Sciences, Inc., Immuron Ltd, and Intercept Pharmaceuticals, Inc.
What is the size of the North America non-alcoholic steatohepatitis treatment market?
North America non-alcoholic steatohepatitis treatment industry is expected to reach USD 23.2 billion by 2032 due to serious complications like cirrhosis and liver cancer if left untreated.
Why is the demand for oral non-alcoholic steatohepatitis treatment growing?
The oral route of administration segment accounted for 63.6% of the market share in 2023 due to several advantages, such as ease of administration, patient compliance, and cost-effectiveness
How big is the non-alcoholic steatohepatitis treatment market?
The non-alcoholic steatohepatitis treatment industry size was USD 5.5 billion in 2023 and is expected to showcase 29.9% CAGR from 2024 to 2032 due to increasing prevalence of metabolic disorders